These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 11264457)

  • 1. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.
    Carlsson A; Waters N; Holm-Waters S; Tedroff J; Nilsson M; Carlsson ML
    Annu Rev Pharmacol Toxicol; 2001; 41():237-60. PubMed ID: 11264457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?
    Benes FM
    Biol Psychiatry; 2009 Jun; 65(12):1003-5. PubMed ID: 19481640
    [No Abstract]   [Full Text] [Related]  

  • 4. [A biochemical theory of schizophrenia].
    Kornhuber HH; Kornhuber J; Kim JS; Kornhuber ME
    Nervenarzt; 1984 Nov; 55(11):602-6. PubMed ID: 6151120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the glutamate, GABA, and dopamine systems in relation to NRH-induced neurotoxicity.
    Benes FM
    Biol Psychiatry; 1995 Dec; 38(12):783-7. PubMed ID: 8750035
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biological basis of schizophrenia: new directions.
    Weinberger DR
    J Clin Psychiatry; 1997; 58 Suppl 10():22-7. PubMed ID: 9265913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction between GABA and dopamine: implications for schizophrenia.
    Garbutt JC; van Kammen DP
    Schizophr Bull; 1983; 9(3):336-53. PubMed ID: 6137869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiologically based treatment interventions in schizophrenia.
    Lewis DA; Gonzalez-Burgos G
    Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dopaminergic receptor activity and the evolution of schizophrenia].
    Fodoreanu L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729
    [No Abstract]   [Full Text] [Related]  

  • 11. Imaging as tool to investigate psychoses and antipsychotics.
    Booij J; van Amelsvoort T
    Handb Exp Pharmacol; 2012; (212):299-337. PubMed ID: 23129337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications.
    Carlsson A; Hansson LO; Waters N; Carlsson ML
    Life Sci; 1997; 61(2):75-94. PubMed ID: 9217267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological perspectives: the role of glutamate in schizophrenia and its treatment.
    Steele D; Moore RL; Swan NA; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2012 Jul; 48(3):125-8. PubMed ID: 22724397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemistry and the schizophrenia. Old concepts and new hypothesis.
    Berger PA
    J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia.
    Van Kammen DP
    Am J Psychiatry; 1977 Feb; 134(2):138-43. PubMed ID: 835733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clozapine, GABA(B), and the treatment of resistant schizophrenia.
    Daskalakis ZJ; George TP
    Clin Pharmacol Ther; 2009 Oct; 86(4):442-6. PubMed ID: 19626000
    [No Abstract]   [Full Text] [Related]  

  • 17. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course.
    Kuepper R; Skinbjerg M; Abi-Dargham A
    Handb Exp Pharmacol; 2012; (212):1-26. PubMed ID: 23129326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments.
    O'Connor WT; O'Shea SD
    Pharmacol Ther; 2015 Jun; 150():47-80. PubMed ID: 25585121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neurobiology of schizophrenia.
    Littrell RA; Schneiderhan M
    Pharmacotherapy; 1996; 16(6 Pt 2):143S-147S; discussion 166S-168S. PubMed ID: 8947997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel targets for drugs in schizophrenia.
    Stone JM; Pilowsky LS
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):265-72. PubMed ID: 17691983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.